Johnson & Johnson's Janssen Pharmaceutica N.V. granted BeiGene exclusive, worldwide rights to develop and commercialize MTKi-327 for all indications

Johnson & Johnson

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

BeiGene Ltd.

China / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced